Member Info for Pie-chart

The tree shake is over.

Big buys like those certainly gives you confidence!

CEO of GenFlow Biosciences (LSE:GENF) (OTC:GENFF), Dr. Eric Leire, is gearing up for a series of meetings with UK-based investors in London this week as interest continues to surge in the realm of anti-ageing research.

Learn more about us here: https://loom.ly/MeQymHs

AN RNS coming soon, stated by Genflow on latest linked-in post. Its time to recover and more. GLA!

A recent Washington Post article delves deep into the societal and personal impacts of the quest for longevity. Tech tycoon Bryan Johnson's personal investment in anti-aging measures and the burgeoning 'Longevity Inc.' market reflect a growing public interest in extending life quality and span.

At GenFlow Biosciences (LSE:GENF) (OTC:GENFF), we're committed to the scientific exploration of longevity, focusing on gene therapies that could potentially slow the aging process. We resonate with the vision of a future where aging is a treatable condition, aligning with the article's insights on the importance of a holistic approach to longevity, encompassing nutrition, exercise, and advanced biomedical research. As we continue to develop our gene therapies, such as our lead compound GF-1002, we are inspired by the ongoing dialogue and are eager to contribute to a future where living longer also means living better.

Read it here: https://lnkd.in/e9iEYipY

#GENF #longevity #healthspan #genetherapy

All of a sudden Genflow is starting to be mentioned here and there. Soon everywhere...

Starting to see traction!

This article underscores the vast untapped potential in the NASH (Nonalcoholic Steatohepatitis) market. The growing prevalence of NASH, fueled by obesity and Type 2 diabetes, underscores the pressing need for effective treatments.

More info here: https://loom.ly/0jnejbo

In the midst of this, GenFlow Biosciences (LSE:GENF) (OTC:GENFF) is stepping up to the challenge with its promising candidate, GF-1002, currently in Phase I/II trials. The potential of GF-1002, showcased in recent pre-clinical programs, marks a hopeful stride towards addressing NASH.

More about our mission here: https://loom.ly/kKTAoxM

#NASH #GENF #Sirtuins #healthspan

This article by the NASH Education Program unravels Non-Alcoholic SteatoHepatitis (NASH), a serious form of non-alcoholic fatty liver disease often shadowed by modern lifestyle habits. NASH affects an estimated 35 million individuals globally, evolving into a leading cause for chronic liver issues and liver transplants. The ripple effect of NASH extends to cardiovascular health, with up to 38% of deaths in NASH patients being directly related to cardiovascular events.

More information here: https://loom.ly/2Pw46nw

At GenFlow Biosciences (LSE:GENF) (OTC:GENFF), we're focused on addressing serious conditions like NASH that impact millions globally. With encouraging feedback from Belgium’s Federal Agency for Medicines and Health Products, we are on a promising trajectory towards initiating clinical trials. This endeavor not only aligns with our goal of reducing the affliction of age-related diseases but also underscores our commitment to enhancing life's quality.

Discover more about our proactive steps towards mitigating NASH and join us on our journey towards fostering better health: https://loom.ly/MeQymHs

#NASH #healthspan #longevity #genetherapy

Meet the #GENFTEAM

Dr Yassine Bendiabdallah, Chairman of GenFlow Biosciences (LSE:GENF) (OTC:GENFF)

Dr. Bendiabdallah (MPharm, PhD, IP) specializes in Functional Medicine and Healthy Ageing and has expertise in Bio-identical Hormone Therapy (BHRT). He worked as an anti-cancer drug discovery scientist with Cancer Research UK at University College London, resulting in multiple publications in academic journals.

After years in academia, Dr. Bendiabdallah co-founded the Zen Healthcare group, a series of pharmacies and wellness clinics in London. He currently serves as Clinical Director, focusing on age reversal therapies, functional medicine, and intravenous micronutrient treatments. Additionally, he sits on the board of several healthcare companies.

Learn more about the Genflow team here: https://loom.ly/PzN7xwA

#GENF #chairman #biotech #ageing #longevity

It's a known fact that the life expectancy of our beloved canine companions varies significantly based on their size and breed, with small breeds averaging 10-15 years and larger breeds around 7-12 years.

The intriguing part? Unlike the general trend in the animal kingdom, larger dogs have shorter lifespans. Scientists speculate that rapid growth spurts in large dogs might lead to a higher likelihood of diseases and cancers.

At GenFlow Biosciences (LSE:GENF) (OTC:GENFF), by targeting the SIRT6 gene, known for its direct link to aging and lifespan through a novel AAV gene therapy, there's potential to not only improve the health of our dogs but possibly extend their joyous companionship.

More information here: https://loom.ly/-z_4j3k

#longevity #healthspan #dogs #SIRT6 #genetherapy

Be fearful when others are greedy!

Be greedy when others are fearful!

The trick is to do the opposite of what your emotions tell you to do.

The fearful have driven the price down.

This is the time to be greedy.

This is the time accumulate & hold.

We all know the trajectory here.

Getting older is something we all experience, but we can take steps to manage how we age. Aging can bring about more health problems, higher healthcare costs, and stress for both ourselves and our loved ones.

By actively working to combat aging, companies like GenFlow Biosciences (LSE:GENF) (OTC:GENFF) are not just potentially extending and enhancing our lives; they are also reducing the strain and responsibility placed on our loved ones and society overall.

Read more here: https://loom.ly/GgZyrHs

Q3 update next week! Great news. It should make for quite the read. So much positive updates will be included. A culmination of all the news we have been eagerly anticipating over the past 3 months.

Two powerhouses in biotech at the 10th ARDD meeting! 🤝

Meet David A. Sinclair A.O., Ph.D., a tenured Professor of Genetics at #HarvardMedicalSchool and a pioneer in longevity research. With 50+ patents and 170 papers cited 85,000+ times, he’s a leading authority in the field. His #NYTBestseller, "Lifespan," and the Lifespan Podcast are revolutionizing how we view aging.

Dr. Sinclair's groundbreaking work aligns with GenFlow Biosciences (LON:GENF)(OTCQB:GENFF) CEO Eric Leire's mission to develop gene-based interventions that slow, halt, or even reverse the aging process.

#ARDD2023 #longevity #aging #healthspan #lifespan #biotech

Gene therapy is on the brink of changing healthcare as we know it. Scientists are exploring innovative ways to treat chronic diseases caused by genetic mutations, offering new hope for conditions once thought untreatable.

GenFlow Biosciences (LON:GENF) (OTCQB:GENFF) is researching a gene transfer technique that involves introducing extra SIRT6 genes into the bloodstream through injection or infusion, without directly affecting carrier cells. This approach aims to potentially prevent permanent harmful gene mutations.

As science and technology converge, we're moving closer to a world where aging is treatable, diseases are caught early, and healthspans are extended!

Read more about our mission here: https://loom.ly/Q_mb6wc

#genetherapy #SIRT6 #healthspan #longevity

Gene therapy is on the brink of changing healthcare as we know it. Scientists are exploring innovative ways to treat chronic diseases caused by genetic mutations, offering new hope for conditions once thought untreatable.

GenFlow Biosciences (LON:GENF) (OTCQB:GENFF) is researching a gene transfer technique that involves introducing extra SIRT6 genes into the bloodstream through injection or infusion, without directly affecting carrier cells. This approach aims to potentially prevent permanent harmful gene mutations.

As science and technology converge, we're moving closer to a world where aging is treatable, diseases are caught early, and healthspans are extended!

Read more about our mission here: https://loom.ly/Q_mb6wc

#genetherapy #SIRT6 #healthspan #longevity

The first day of ARDD 2023 was a testament to the maturing longevity biotechnology industry. The event set a high bar for the days to follow, offering a rich blend of content that spanned from basic science to clinical translation, all aimed at extending the healthy human lifespan.

Companies like GenFlow Biosciences (LON:GENF) (OTCQB:GENFF) are leading the way to a promising future, spearheading innovative research and breakthroughs that have the potential to reshape how we approach aging and longevity. As we continue to witness the progress and collaboration within the longevity biotechnology sector, there's a growing sense of optimism that the vision of healthier, extended lifespans is indeed within reach.

Find out more here: https://loom.ly/Z0NdaV4

#ARDD2023 #longevity #biotech #healthspan #GENF

Did you know that only 3% of elephants get cancer? These majestic creatures possess a secret weapon in their genome – twenty copies of a tumor suppressor gene called p53, compared to the single copy in most mammals, including humans.

This p53 gene acts as a vigilant DNA watchdog, repairing damaged DNA or eliminating compromised cells. But there's more to the story: elephants also up-regulate the LIF6 gene in response to DNA damage, providing superior DNA maintenance that shields them from cancer.

Ageing, like cancer, involves complex biological processes. Drawing inspiration from elephants, GenFlow Biosciences (LON:GENF) (OTCQB:GENFF) is pioneering gene-based interventions targeting SIRT6, a gene involved in aging regulation and DNA integrity. Our visionary approach offers the potential to slow, halt, or even reverse the ageing process.

Read more about it here: https://loom.ly/SHKthjM

#healthspan #ageing #elephants #biotech #SIRT6

Mainstream medicine, while successful in extending lifespan, often sacrifices quality of life while treating age-related illnesses like heart disease, cancer, Alzheimer's, and type 2 diabetes. In his book, "Outlive: The Science and Art of Longevity," Dr. Peter Attia introduces a fresh perspective, offering personalized, proactive longevity strategies that prioritize both vitality and years. https://loom.ly/C_7cnc4

At GenFlow Biosciences (LON:GENF) (OTCQB:GENFF) we believe a longer, healthier life is achievable through the development of novel therapeutics that can potentially halt or slow the ageing process. Learn more about our mission here: https://loom.ly/1vAP6LA

#outlive #longevity #healthspan #genetherapy

From heart health to cognitive decline, understanding the impact of age on diseases like arthritis, cardiovascular issues, Alzheimer's, osteoporosis, and macular degeneration is crucial.

Exciting genetic research suggests interventions, like targeting the SIRT6 gene, could slow down aging, adding years to our lives and increasing our healthspan. At GenFlow Biosciences (LON:GENF) (OTCQB:GENFF), we believe quality of life matters.

Read more about it here: https://loom.ly/lDMto0s

#Ageing #diseases #healthspan #sirt6